Lactobacillus rhamnosus Rosell®-11

What is Lactobacillus rhamnosus Rosell®‑11—and why is it in Biotic⁺?

Rosell®‑11 is a proven, trademarked strain of L. rhamnosus, known for its:

Strong survivability through the digestive tract, reaching the gut alive in most users
Qualified Presumption of Safety status from EFSA, Health Canada, TGA, and other authorities

🤔 What benefits does Rosell®‑11 offer?

Rosell®‑11 is an acid-resistant strain, meaning its more likely to survive the harsh environments of human digestion (increased bioavailability), proven in human trials (Firmesse et al., 2008).

Clinical and lab studies show that Rosell®‑11:

Supports digestive health, helping reduce antibiotic-associated diarrhoea and C. difficile infections (Evans et al., 2016)
Strengthens the gut barrier, promoting mucus production and epithelial cell renewal to fend off pathogens (Sherman et al., 2005)
Inhibits harmful bacteria and immune health, reducing inflammatory pathway signalling (Wood et al., 2007)

🤔 Why choose this trademarked strain?

Strain-specific quality: Rosell®‑11 is consistently strain-verified, ensuring reliable potency and safety
Research-backed: Decades of scholarly and clinical research support its benefits
Robust and acid resistant: Designed for real-world use—survives storage, processing, and digestion without refrigeration—thanks to proven encapsulation technologies

🤔 How does it support your health?

Survives stomach acid and bile, so it reaches your gut intact
Binds to gut cells, promotes mucus, and supports barrier integrity
Limits pathogen growth—helping reduce IBS, antibiotic-associated diarrhoea, and infections

🤔 Why include it in Biotic⁺?

We chose Rosell®‑11 because it’s a trusted, science-backed strain that delivers live, stable probiotic benefits—supporting gut balance, immune resilience, and digestive comfort in a safe, traceable, and effective way.

📚 References:

Evans M. et al., (2016), ‘Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial’. British Journal of Nutrition, 116(1):94-103. doi: 10.1017/S0007114516001665. Epub 2016 May 12.

Firmesse O. et al., (2008), ‘Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying microbiota equilibrium as assessed by real-time polymerase chain reaction’. J. Mol. Microbiol. Biotechnol.,14(1-3):90-9.

Sherman PM. et al. (2005) Probiotics reduce enterohemorrhagic Escherichia coli 0157:H7- and enteropathogenic E. coli 0127:H6- induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infection and Immunity., 73 (8):51835188

Wood C. et al. (2007) Interactions in the mucosal microenvironment: Vasoactive intestinal peptide modulates the down-regulatory action of Lactobacillus rhamnosus on LPS induced interleukin-8 production by intestinal epithelial cells. Microbial Ecology in Health and Disease. 1-10